Bausch + Lomb Announces Statistically Significant Topline Results from Second Phase 3 Trial of NOV03

Wednesday, October 6 2021 | 11 h 29 min | News, Press Release

Bausch + Lomb and Novaliq announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational...

Read More

Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE

Friday, June 4 2021 | 15 h 48 min | News, Press Release

Bausch + Lomb, along with Clearside Biomedical, a biopharmaceutical company dedicated to developing and delivering treatments that restore and...

Read More

Bausch + Lomb Announces Results from First Phase 3 Trial of NOV03

Thursday, April 15 2021 | 09 h 33 min | Dry Eye, News, Press Release

Bausch + Lomb and Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced statistically significant...

Read More

Bausch Advances Novel Dry Eye Therapeutic to Phase 3

Tuesday, December 29 2020 | 07 h 28 min | Dry Eye, Latest News, News, Vision Science

Quebec based B+L has announced the second of two Phase 3 studies studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a...

Read More

Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled

Monday, November 16 2020 | 10 h 26 min | News, Press Release

Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and...

Read More